supporting data for "The Role of Probiotics in Regulating Gut Microbiome in the Development of Steatosis liver disease (SLD): from metabolic dysfunction-associated steatotic liver disease (MASLD) to Hepatocellular carcinoma (HCC)"

Metabolic associated fatty liver disease (MASLD) has been on the rise globally over the past decade, affecting approximately 30% of adults worldwide. MASLD is a significant contributor to hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths in 2020. Despite the increasing burden of MASLD-associated HCC, there are currently no effective therapeutic interventions available. In light of this, research has focused on targeting the gut microbiome using probiotics as a promising treatment strategy for MASLD-HCC via the gut-liver axis.
Prohep, a novel probiotics mixture containing 8 well-studied probiotic species, has shown efficacy in suppressing tumor growth in an HCC xenograft mice model. Here it was hypothesized that Prohep reveal no toxicity for daily consumption and is effective in prevention and inhibition of MASLD-HCC throughout its progression.